Current treatment of lupus nephritis
Current treatment of lupus nephritis
复制标题
DOI：
10.1177/0961203308090029
复制
发表时间：
2008-01-01
期刊：
影响因子：
2.6
通讯作者：
Ginzler, E. M.
中科院分区：
文献类型：
--
作者：
Houssiau, F. A.;Ginzler, E. M.
本篇关于狼疮性肾炎治疗的综述基于随机临床试验的结果，讨论了治疗原则以及当前诱导和维持治疗的选择。吗替麦考酚酯和静脉注射环磷酰胺各自的位置是平衡的，兼顾了疗效、安全性和患者的角度。作者预计，几年后，当获得吗替麦考酚酯诱发狼疮肾炎患者的长期数据时，长期以来一直作为“标准治疗”的静脉注射环磷酰胺可能只会在特殊情况下使用，例如有记录的坏死性血管炎。
This review on the management of lupus nephritis is based on the results of randomized clinical trials, and discusses the principles of treatment and the current options for induction and maintenance therapy. The respective place of mycophenolate mofetil and intravenous cyclophosphamide are balanced, taking into account efficacy, safety and patients' perspective. The authors anticipate that, in a few years, when long-term data on lupus nephritis patients induced with mycophenolate mofetil becomes available, it is probably that intravenous cyclophosphamide, which has been for so long the 'standard of care', will be prescribed only in specialized conditions such as documented necrotizing vasculitis.